Case studies
Each case study shows how evidence, hierarchy, and communication were tightened around a specific review need.
Commercial Positioning
The company had promising biology, but its narrative was diffuse. Investors and prospective partners could not quickly evaluate mechanism, indication fit, biomarker logic, or differentiation.
Outcome Measures
The team needed a sharper rationale for endpoint selection, patient relevance, and mechanism-linked readouts before early clinical planning advanced.
Commercial Positioning
A manuscript and related supporting materials were scientifically sound but difficult to streamline for co-authors and reviewer-facing clarity.
Asset Development
Leadership needed a rapid assessment of mechanism plausibility, translational risks, and white-space opportunity without commissioning a full diligence engagement.
Commercial Positioning
External materials were accurate but too technical for business audiences and too generic for scientific audiences, weakening differentiation.
Asset Development
A founder-led team needed to make a near-term go-or-refine call, but mechanism, endpoint, and market assumptions were scattered across decks and meeting notes.
Outcome Measures
A late design sprint exposed that the study objective and endpoint architecture no longer matched, creating interpretation risk and reviewer friction.
Commercial Positioning
A team heading into external conversations had strong science but weak narrative discipline, making it difficult to answer tough comparator and confidence questions.
“NociWise helped us sharpen the scientific logic behind our pain program and communicate it with much greater clarity.”
CEO, preclinical biotech
“What stood out was the ability to identify where the translational story was strong, where it was vulnerable, and how to present it credibly.”
Head of Strategy, early-stage therapeutics company
“Their edits improved much more than the language. They improved the argument.”
Principal Investigator, translational neuroscience collaboration
“NociWise made it easier for scientific and non-scientific stakeholders to align on what mattered.”
Founder, stealth biotech
“The final brief helped us move from broad scientific interest to a much clearer decision framework.”
Operating Partner, health-tech investor
Next step
Share the milestone, review audience, and current point of friction. We will recommend the most relevant support path.
